| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Oncology | ||
phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Oncology | ||
phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Compugen Ltd.$2.38
+0.1 (+4.39%)
D 31Pipeline Score Richly Valued Biotech · Clinical
Market Cap
264.75 M
EPS
0.37
P/E Ratio
7.65 $
Value Trade
1.74 M
-5.08 %
Week
-2.44 %
1 Month
59.09 %
3 Month
84.21 %
6 Month
-66.71 %
5 Year
-72.77 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
103.76 K
52 Week Range
1.30 - 3.24
% held by Insiders
2.19 %
% held by Institutions
15.27 %
Enterprise Value
132.73 M
Total Shares
93.54 M
Short %
3.24 %
Float Shares
93.48 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Compugen Ltd.
564Total events
6Upcoming
46Tier-1 (high impact)
2015 – 2036Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
◆Poster PresentationCOM701Presentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-10-18 | COM701 (anti-PVRIG antibody) | phase 1 data readout | Phase 1 | — | – | – | – |
2025-10-18 | COM701 (anti-PVRIG antibody) | phase 1 data readout | Phase 1 | — | – | – | – |
2025-10-18 | COM701 (anti-PVRIG antibody) | phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
D31
Pipeline Score $38M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.1x
rNPV / MCap Top 41%
Micro Cap (rank 540 of 913)
Percentile RankCompugen Ltd. faces pipeline headwinds (31/100), with $378M risk-adjusted pipeline value, led by COM701 in Advanced Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose escalation: COM902 monotherapy. Small molecule | Advanced Cancer | Phase 1 | NCT04354246 | 5% | $126M | COMPLETED | 94 | AVERAGE | C (46) | Apr 1, 2026 | MODERATE_RISK | MEDIUM Jun 12, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
COM701 | platinum-resistant ovarian cancer | Phase 1 | 2025-10-13 | The pooled analysis of 60 evaluable patients with platinum-resistant ovarian cancer demonstrated that COM701 was well tolerated and showed consistent, durable responses, particularly in patients without liver metastases, supporting its potential as a maintenance therapy. Read More | Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 Read More | |
COM701 | platinum-resistant ovarian cancer | Phase 1 | 2025-10-13 | The pooled analysis of 60 evaluable patients with platinum-resistant ovarian cancer demonstrated that COM701 was well tolerated and showed consistent, durable responses, particularly in patients without liver metastases, supporting its potential as a maintenance therapy. Read More | Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 Read More | |
COM701 | platinum-resistant ovarian cancer | Phase 1 | 2025-10-13 | The pooled analysis of 60 evaluable patients with platinum-resistant ovarian cancer demonstrated that COM701 was well tolerated and showed consistent, durable responses, particularly in patients without liver metastases, supporting its potential as a maintenance therapy. Read More | Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CGEN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CGEN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CGEN▲ +6.4%on this news
Compugen to Participate in BTIG Biotechnology Conference 2026
Compugen Ltd. will participate in the BTIG Biotechnology Conference 2026, scheduled for July 28-29, 2026. The company will present and hold one-on-one meetings with attendees. Compugen is known for its AI/ML-powered platform for cancer immunotherapy and has several clinical trials underway for its drug candidates.
Read more →CGENCompugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
Compugen Ltd. announced it will release its second quarter 2026 financial results on August 3, 2026, before U.S. markets open. A conference call and webcast will follow at 8:30 AM ET to discuss the results and provide a corporate update. The company is known for its AI/ML-driven cancer immunotherapy development.
Read more →CGENCompugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
Compugen Ltd. presented a trial-in-progress poster for the MAIA-ovarian adaptive platform trial of COM701 at the ESMO Gynaecological Cancers Congress 2026. This trial evaluates COM701, a potential first-in-class anti-PVRIG antibody, as a maintenance treatment for relapsed platinum-sensitive ovarian cancer. Initial data from the trial is anticipated by Q1 2027.
Read more →CGENCompugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
Compugen Ltd. announced it will present a trial-in-progress poster on its MAIA-ovarian Phase 1 study of COM701 at the ESMO Gynaecological Cancers Congress 2026. The study evaluates the safety and efficacy of COM701 in treating relapsed platinum-sensitive ovarian cancer. The presentation is scheduled for June 18, 2026, in Copenhagen.
Read more →CGENCompugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
Compugen Ltd. announced its participation in Jones Trading's Fireside Chat Series focused on AI/ML-based drug development. The event is scheduled for June 15, 2026, and will feature insights from Compugen's management. The company is known for its AI/ML powered platform for cancer immunotherapy discovery and has several clinical-stage programs underway.
Read more →CGENCompugen Reports First Quarter 2026 Results
Compugen Ltd. reported its first quarter 2026 financial results, highlighting the ongoing enrollment in the COM701 MAIA-ovarian trial across clinical sites in the U.S., Israel, and France, with an interim analysis expected by Q1 2027. The company also noted the advancement of its partner AstraZeneca's rilvegostomig through 11 Phase 3 trials, with new data to be presented. Compugen maintains a solid financial position with a cash runway projected into 2029, leveraging partnerships that could yield substantial milestone payments. Despite these optimistic developments, the company reported an increased net loss compared to the previous year, raising potential financial concerns.
Read more →CGENCompugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Compugen Ltd. will present at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026. The event will feature a live webcast accessible via the company's Investor Relations page. Compugen is recognized for its AI/ML-powered therapeutic discovery platform, focusing on novel cancer immunotherapies.
Read more →CGENCompugen to Release First Quarter 2026 Results on Monday, May 18, 2026
Compugen Ltd. announced it will release its first quarter 2026 financial results on May 18, 2026, before U.S. markets open. A conference call and webcast will follow at 8:30 AM ET to discuss the results and provide corporate updates. The company continues to develop innovative cancer immunotherapy programs.
Read more →CGEN▲ +8.3%on this news· ran to +26% by day 3
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
Compugen Ltd. announced its participation in the 25th Annual Needham Virtual Healthcare Conference, scheduled for April 13, 2026. The company's management will present from 8:45 to 9:25 AM ET, with a live webcast available on their website. Compugen is known for its AI-driven drug target discovery and has several promising cancer immunotherapy programs.
Read more →CGEN▲ +24.3%on this news
Compugen Reports Fourth Quarter and Full Year 2025 Results
Compugen Ltd. reported strong financial results for Q4 and full year 2025, highlighting a strategic monetization deal with AstraZeneca that extends its cash runway into 2029. The company initiated new clinical trials and presented supportive data for its MAIA-ovarian trial at ESMO 2025. Despite significant revenue growth, Compugen acknowledges risks related to clinical development and reliance on partnerships.
Read more →CGEN▲ +5.3%on this news
Compugen to Participate in Upcoming Investor Conferences
Compugen Ltd. (NASDAQ: CGEN) announced its participation in two upcoming investor conferences, the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Partners 2026 Global Healthcare Conference. The company will engage in fireside chats and 1x1 meetings at both events. Compugen is known for its AI/ML-powered computational drug discovery platform and has several promising cancer immunotherapy programs in development. The participation in these conferences highlights the company’s efforts to connect with investors and discuss its innovative pipeline.
Read more →CGENCompugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
Compugen Ltd. announced the release date for its fourth quarter and full year 2025 financial results, scheduled for March 2, 2026, before market opening. The company will also host a conference call and webcast at 8:30 AM ET to review the results. As a clinical-stage cancer immunotherapy firm leveraging AI/ML, Compugen aims to advance its therapeutic discoveries, including its innovative drug candidates targeting TIGIT and PVRIG.
Read more →CGENCompugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
Compugen Ltd. has appointed Michele Holcomb, Ph.D., as an independent director, effective February 11, 2026. Dr. Holcomb brings over 30 years of experience in the biotech and pharmaceutical sectors, which is expected to strengthen the board's capabilities. Compugen is well-positioned financially and has multiple promising clinical programs underway.
Read more →CGENCompugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
Compugen Ltd. has entered into an agreement with AstraZeneca to monetize a portion of future royalties from rilvegostomig, enhancing its financial stability. This strategic move is expected to extend Compugen's cash runway into 2029, allowing continued advancement of its immuno-oncology pipeline. The deal underscores the potential value of rilvegostomig and Compugen's innovative approach to cancer treatment.
Read more →CGENCompugen Reports Third Quarter 2025 Results
Compugen Ltd. reported its financial results for Q3 2025, highlighting a focus on its differentiated cancer immunotherapy pipeline. The company emphasized positive data from ESMO regarding its anti-TIGIT antibodies and ongoing clinical trials. Despite a decline in revenue and a net loss, Compugen maintains a strong cash position, expected to last into Q3 2027.
Read more →CGEN▼ -6.9%on this news
Compugen to Participate in Stifel 2025 Healthcare Conference
Compugen Ltd. announced its participation in the Stifel 2025 Healthcare Conference, scheduled for November 11, 2025. The company's management will engage in a fireside chat during the event in New York City. Compugen is recognized for its innovative research in cancer immunotherapy and has several proprietary product candidates in development. A live webcast of the session will be accessible on their website, along with a replay after the event.
Read more →CGEN▼ -5%on this news
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
Compugen Ltd. announced it will release its third quarter 2025 financial results on November 10, 2025, before U.S. markets open. A conference call and webcast will follow at 8:30 AM ET for management to review the results and provide updates. The company is known for its AI/ML-powered drug discovery platform and has multiple candidates in various phases of development.
Read more →CGEN▲ +21.1%on this news
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
Compugen announced a pooled analysis of COM701's efficacy in platinum-resistant ovarian cancer, revealing positive outcomes in a subset of patients. The findings will be presented at ESMO 2025, highlighting the potential of COM701 as a maintenance therapy. The company is also conducting the MAIA-ovarian trial to further evaluate COM701's effectiveness.
Read more →CGEN▲ +9.8%on this news
Compugen to Present at SITC 2025
Compugen Ltd. announced that it will present a trial in progress for its anti-IL18BP antibody, COM503, at the upcoming SITC 2025 conference. The presentation will take place on November 7, 2025, and will be led by Dr. Manish Sharma. This trial focuses on participants with advanced solid malignancies, showcasing Compugen's commitment to cancer immunotherapy development.
Read more →CGENCompugen to Present Research at the Single Cell Genomics 2025 Conference
Compugen Ltd. announced its participation in the Single Cell Genomics 2025 Conference in Stockholm, where it will present research on spatial transcriptomics in colorectal cancer. The presentation aims to demonstrate Compugen's computational capabilities in understanding cancer biology, which could inform therapeutic strategies. The event is scheduled for September 15-17, 2025.
Read more →CGENCompugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Compugen Ltd. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The fireside chat will be accessible on demand starting September 5, 2025. Compugen is known for its AI/ML-powered drug discovery platform and has several candidates in various phases of development, including COM701 and COM902.
Read more →CGENCompugen Reports Second Quarter 2025 Results
Compugen Ltd. reported its second quarter 2025 results, highlighting progress in its clinical trials, including the dosing of the first patient in the MAIA-ovarian trial for COM701. The company has a solid cash position expected to fund operations into 2027, despite a significant decrease in revenue from the previous year. Upcoming presentations at ESMO 2025 include a pooled analysis of COM701's effectiveness in platinum-resistant ovarian cancer. The ongoing development of rilvegostomig in partnership with AstraZeneca also presents potential revenue opportunities for Compugen.
Read more →CGENCompugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
Compugen Ltd. announced it will present a pooled analysis of three Phase 1 trials for COM701, targeting platinum resistant ovarian cancer, at ESMO 2025 in Berlin. The analysis will assess COM701's effectiveness both as a monotherapy and in combination therapies among heavily pretreated patients. The presentation, scheduled for October 18, 2025, is expected to provide insights into the drug's potential impact on this challenging form of cancer. Compugen is focused on developing therapeutic strategies through advanced AI technologies.
Read more →CGENCompugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025
Compugen Ltd. announced it will release its second quarter 2025 financial results on August 6, 2025. Before the U.S. financial markets open, management will provide insights through a conference call and webcast. The company is engaged in developing cancer immunotherapies and has two product candidates in Phase 1 development. Compugen is known for leveraging AI/ML technologies in its drug discovery processes.
Read more →CGENCompugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer
Compugen Ltd. has announced the first patient has been dosed in the global randomized sub-trial of their COM701 maintenance therapy for patients with relapsed platinum-sensitive ovarian cancer. This trial aims to evaluate the efficacy and safety of COM701, a potential first-in-class anti-PVRIG antibody. Interim results are expected in the second half of 2026, with hopes that positive outcomes could pave the way for wider use of COM701. The study highlights Compugen's commitment to addressing significant unmet needs in cancer therapy.
Read more →CGENCompugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
Compugen Ltd. (Nasdaq: CGEN) will present AI/ML driven predictive computational research at two important scientific conferences in June and July 2025. The presentations will focus on mechanisms of immune evasion and immunotherapy resistance in various subtypes of triple-negative breast cancer (TNBC). The company is leveraging its predictive computational discovery platform, UnigenTM, for developing cancer immunotherapies and has multiple candidates in different stages of clinical development. Compugen aims to enhance anti-cancer immunity through its pipeline of immuno-oncology research programs.
Read more →CGENCompugen Reports First Quarter 2025 Results
Compugen Ltd. reported financial results for Q1 2025 and shared updates on its clinical programs. The company initiated a trial for COM701 maintenance therapy and continues to advance its Phase 1 trial for GS-0321, an anti-IL18BP antibody. Partner AstraZeneca expanded its rilvegostomig program to ten Phase 3 trials across various cancers, with early data expected at the ASCO 2025 conference. Compugen maintains a robust financial position, projecting sufficient funds to cover operations into 2027, despite a slight decrease in revenues compared to the previous year.
Read more →CGENCompugen Announces Leadership Transitions Effective September 2025
Compugen Ltd. has announced significant leadership changes that will take effect in September 2025. Dr. Anat Cohen-Dayag will transition to the role of Executive Chair of the Board, while Dr. Eran Ophir is appointed as the new President and CEO. The announcement underscores the company's continued growth and strategic direction in the immuno-oncology sector. Dr. Cohen-Dayag has highlighted the achievements of Compugen under her leadership, while Dr. Ophir expresses a commitment to driving further innovation and success.
Read more →CGEN▼ -7.4%on this news
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025
Compugen Ltd. announced the release of its first quarter 2025 financial results scheduled for May 19, 2025, before the U.S. markets open. The company will conduct a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. Compugen is known for its cancer immunotherapy developments and is currently advancing multiple proprietary product candidates in clinical stages.
Read more →CGENCompugen to Participate in Multiple Virtual Investor Conferences in April 2025
Compugen Ltd. announced its participation in several virtual investor conferences scheduled for April 2025. The events include the H.C. Wainwright AI Based Drug Discovery & Development Conference, the Needham Virtual Healthcare Conference, and Stifel's Targeted Oncology Forum. Management will engage through fireside chats and 1x1 meetings, allowing for direct interaction with investors. This initiative emphasizes Compugen's ongoing communication strategy while highlighting its innovations in cancer immunotherapy.
Read more →CGEN▼ -7.2%on this news
Compugen Reports Fourth Quarter and Full Year 2024 Results
Compugen Ltd. reported its financial results for Q4 and full-year 2024, highlighting advancements in its clinical pipeline, including COM701 for ovarian cancer, which is set to enter a randomized adaptive trial in Q2 2025. The company remains in a strong financial position with a cash runway expected to extend into 2027, supported by recent milestone payments from partners Gilead and AstraZeneca. Despite a net loss in 2024, the company's diverse pipeline and partnerships are anticipated to drive potential growth in the coming years.
Read more →CGEN▼ -5.7%on this newsshared move
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
Compugen Ltd. announced its participation in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference, taking place in Miami Beach, Florida. The event is scheduled for March 11, 2025, at 8:00 AM ET, and a live webcast will be available on the company's website. Compugen, known for its innovative cancer immunotherapies, is developing several promising therapeutic candidates, which includes its proprietary products in various stages of clinical trials.
Read more →CGENCompugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics
Compugen has partnered with Ultima Genomics to enhance its AI/ML predictive computational discovery platform, Unigen. This collaboration leverages Ultima's UG 100 sequencing platform to gain new insights into gene structure relevant to immuno-oncology. Findings were presented at the AGBT 2025 General Meeting, demonstrating high consistency in single-cell expression levels and the potential to develop new immunotherapies. Compugen aims to use these insights to further refine its predictive models and accelerate novel drug target discovery.
Read more →CGENCompugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025
Compugen Ltd. announced it will release its fourth quarter and full year 2024 financial results on March 4, 2025, before U.S. markets open. A conference call and webcast will be held at 8:30 am ET for an overview of the financial results and a corporate update. The company is noted for its focus on cancer immunotherapy, with several product candidates currently in various phases of development, including COM701 and COM902. Compugen is headquartered in Israel and operates offices in San Francisco, CA.
Read more →CGENCompugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Compugen Ltd. is set to participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. The virtual event will feature discussions on their clinical-stage cancer immunotherapy developments, including products COM701 and COM902, which are in Phase 1 trials. Compugen is leveraging its computational discovery platform to identify new therapeutic targets. This appearance underscores the company’s commitment to advancing its immunotherapy pipeline and reaching potential investors.
Read more →CGENCompugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Compugen has successfully dosed the first patient in a Phase 1 clinical trial for COM503, an innovative anti-IL-18 binding protein antibody, which is being studied as both a monotherapy and in combination with Gilead's zimberelimab for advanced solid tumors. The trial is aimed at determining the safety, tolerability, and pharmacokinetics of the treatment. Compugen's collaboration with Gilead not only advances this promising therapy but also ensures significant financial backing for further development.
Read more →CGEN▲ +5.9%on this news
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen Ltd. announced the granting of a new U.S. patent for COM902, a reduced Fc anti-TIGIT antibody, which covers its use in combination with anti-PD-1 and anti-PVRIG antibodies for cancer treatment. The patent is expected to enhance Compugen's intellectual property portfolio, offering broader protection for triple combination therapies. The company plans to evaluate COM701, its anti-PVRIG antibody, in an upcoming study designed to optimize treatment combinations. However, Compugen's clinical development faces inherent risks, including potential delays and dependency on collaboration agreements.
Read more →CGEN▼ -8%on this news· ran to -19% by day 3
Compugen Reports Third Quarter 2024 Results
Compugen Ltd. reported its third quarter 2024 financial results, highlighting promising clinical data for COM701 in hard-to-treat cancers and plans to start a Phase 1 trial for COM503. The firm anticipates significant regulatory and commercial opportunities in ovarian cancer treatment with COM701 and expects to initiate an adaptive platform trial in Q2 2025. Financially, the company posted a net profit of approximately $1.3 million, showing improved performance compared to the previous year. Compugen also has a solid cash position, projected to support operations through 2027.
Read more →CGENCompugen to Participate in Stifel 2024 Healthcare Conference
Compugen Ltd. (CGEN) has announced its participation in the Stifel 2024 Healthcare Conference, scheduled for November 18, 2024, in New York City. The management will engage in a fireside chat to discuss the company's innovative approaches to cancer immunotherapy and its development pipeline. Compugen is known for its computational target discovery platform and has two product candidates in Phase 1 development. A live webcast of this event will be available for interested investors.
Read more →CGENCompugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
Compugen Ltd. has announced positive findings regarding the anti-tumor activity and safety of its combination therapy, which includes COM701, COM902, and pembrolizumab, for patients with platinum resistant ovarian cancer. The results will be presented at the Society for Immunotherapy of Cancer (SITC) 2024 conference. Executives indicate that the therapy demonstrates promising durability and safety, addressing significant unmet needs in advanced ovarian cancer treatment. The data may support introducing COM701 to earlier lines of ovarian cancer therapy.
Read more →CGENCompugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Compugen Ltd. has announced it will release its third quarter financial results on November 12, 2024, prior to the opening of U.S. markets. The management will host a conference call to discuss the financial results and provide updates on corporate developments, including data presented at the Society for Immunotherapy of Cancer meeting. The company is focused on cancer immunotherapy and is currently advancing several product candidates through various stages of clinical development.
Read more →CGENCompugen to Present New Clinical Data at SITC 2024
Compugen Ltd. announced that it will present new clinical data on its drug combination of COM701, COM902, and pembrolizumab at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 8-10, 2024. This data highlights the anti-tumor activity and safety of the treatment in heavily pre-treated patients with platinum-resistant ovarian cancer. The presentation will be led by Dr. Oladapo Yeku from Massachusetts General Hospital, showcasing interim results from a Phase I trial. Compugen is focused on cancer immunotherapy and has promising candidates in its pipeline.
Read more →CGEN▲ +8.2%on this news
Compugen to Present at Single Cell Genomics 2024 Conference
Compugen Ltd. announced that Dr. Roy Granit will present a poster at the Single Cell Genomics 2024 conference, focusing on the application of AI in studying the immune checkpoint PVRIG using single-cell and spatial transcriptomics. The findings suggest PVRIG inhibition may hold therapeutic promise in previously untreated indications. Compugen’s AI/ML-driven Unigen platform continues to advance drug target discovery and cancer immunotherapy development. The presentation will occur from September 16-18, 2024, in Corinthia, Greece.
Read more →CGEN▲ +6.8%on this news
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Compugen Ltd. has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, where management will present virtually. The presentation will be accessible on demand for 30 days starting September 9, 2024. Compugen is noted for its cancer immunotherapy innovations and has multiple product candidates in various stages of development, including Phase 1 and Phase 3 trials in collaboration with AstraZeneca. Their pipeline continues to expand with early-stage programs targeting immune resistance mechanisms.
Read more →CGENCompugen Reports Second Quarter 2024 Results
Compugen Ltd. reported its second-quarter 2024 financial results, highlighting positive developments including FDA clearance for COM503 and a $30 million milestone payment from Gilead. The company is progressing in its clinical trials, with data expected in Q4 2024 for multiple studies related to ovarian cancer and other treatments. Furthermore, Compugen's financial health is strong, with a cash runway anticipated to extend into 2027, bolstered by its partnerships with Gilead and AstraZeneca. However, challenges remain, including the need for significant revenue from collaborations and the recent net loss reported.
Read more →CGENCompugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
Compugen Ltd. has received FDA clearance for its investigational new drug application for COM503, triggering a $30 million milestone payment from Gilead Sciences. This development allows Compugen to initiate a Phase 1 clinical trial to assess the safety and tolerability of COM503 for the treatment of advanced solid tumors, which is expected to begin in the fourth quarter of 2024. The antibody therapy aims to harness cytokine biology for cancer treatment and could represent a significant advancement in the field. Compugen is well-positioned financially to support the upcoming trial and further development.
Read more →CGENCompugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
Compugen Ltd. announced the upcoming release of its second quarter 2024 financial results on August 6, 2024, before U.S. markets open. The company will host a conference call at 8:30 AM ET to discuss these results and provide a corporate update. Compugen specializes in cancer immunotherapy, with key product candidates including COM701 and COM902, aimed at targeting various pathways in cancer treatment. Their ongoing development with AstraZeneca and Gilead highlights the company's active engagement in the immuno-oncology field.
Read more →CGEN▼ -5.3%on this news
Compugen to Present at Upcoming Antibody Industrial Symposium
Compugen Ltd. has announced that Pierre Ferré will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the upcoming Antibody Industrial Symposium in Montpellier, France. The presentation is scheduled for June 21, 2024. Compugen, a clinical-stage cancer immunotherapy company, is noted for its innovative work in computational target discovery and has developed proprietary product candidates COM701 and COM902. The company actively collaborates with industry leaders, including AstraZeneca and Gilead, to advance its therapeutic pipeline.
Read more →CGEN▼ -8%on this news
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen Ltd. has announced that it will receive a $5 million milestone payment from AstraZeneca triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig for nonsquamous non-small cell lung cancer. This trial, TROPION-Lung10, assesses rilvegostomig's efficacy as both a monotherapy and in combination with datopotamab deruxtecan against pembrolizumab. Compugen's collaboration with AstraZeneca reflects a strategic expansion of its pipeline. The trial aims to enroll approximately 675 patients across more than 14 countries.
Read more →CGEN▼ -17.5%on this news
Compugen Reports First Quarter 2024 Results
Compugen Ltd. reported its financial results for Q1 2024 and outlined progress in its clinical studies, notably presenting data at ASCO 2024. The company is positioned to submit an IND for its COM503 therapy in late 2024 and is advancing trials in collaboration with AstraZeneca. Despite a reported net loss, Compugen's solid cash position is expected to support operations through 2027, with upcoming data presentations anticipated to provide insights into their new cancer therapies.
Read more →CGENCompugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
Compugen Ltd. announced the publication of a peer-reviewed paper in Cancer Immunology Research, highlighting the unique biology of PVRIG and its therapeutic potential in cancer immunotherapy. The study indicates that blocking PVRIG alongside conventional immunotherapies may enhance immune responses in non-inflamed tumors. CEO Anat Cohen-Dayag emphasized the promising clinical results of the triple blockade involving PVRIG. However, the company faces inherent risks associated with clinical development and external factors such as geopolitical tensions.
Read more →CGEN▲ +5.7%on this news· ran to -17% by day 3shared move
Compugen Appoints David Silberman as Chief Financial Officer
Compugen Ltd. has appointed David Silberman as its new Chief Financial Officer, effective August 15, 2024. Silberman, who previously served as CFO at Oramed Pharmaceuticals, is expected to contribute significantly to Compugen's future projects and financial strength. The appointment coincides with a planned busy year for the company, which is focused on developing new cancer immunotherapies and improving patient outcomes. Alberto Sessa, the outgoing CFO, has been acknowledged for his critical role in advancing the company’s mission since 2022.
Read more →CGENCompugen to Release First Quarter 2024 Results on Monday, May 20, 2024
Compugen Ltd. has announced that it will release its first quarter 2024 financial results on May 20, 2024, prior to the opening of U.S. financial markets. A conference call and webcast will accompany the results, allowing for a corporate update. Compugen is involved in the development of cancer immunotherapies and has several proprietary product candidates under its pipeline. The company emphasizes its predictive computational discovery capabilities in identifying drug targets.
Read more →CGENCompugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Compugen Ltd. announced it will present new clinical data on its investigational therapy COM701, an anti-PVRIG antibody, in combination with COM902 and pembrolizumab for microsatellite stable colorectal cancer with liver metastases. The presentation will take place at the ASCO annual meeting scheduled for May 31 to June 4, 2024, in Chicago, Illinois. This combination therapy aims to evaluate its preliminary anti-tumor activity in patients, representing a significant step in Compugen's cancer immunotherapy development efforts.
Read more →CGENCompugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Compugen Ltd. has announced the online publication of a peer-reviewed paper in Cancer Immunology Research, highlighting the therapeutic potential of COM503, an anti-IL-18BP blocker antibody. The paper details how COM503 could unleash the natural activity of IL-18 to stimulate the immune system and inhibit cancer growth. Compugen plans to expedite COM503's development, aiming for an IND filing and initiation of a Phase 1 study this year. The company continues to leverage its computational discovery capabilities to address cancer immunotherapy challenges.
Read more →CGENCompugen to Participate in Two Upcoming Investor Conferences
Compugen Ltd. (NASDAQ: CGEN) announced its participation in two upcoming investor conferences in April 2024. The events include the 23rd Annual Needham Virtual Healthcare Conference and the Canaccord Genuity Horizons in Oncology Virtual Conference. Compugen aims to provide insights into its pipeline of cancer immunotherapy candidates and its computational target discovery approach during these sessions.
Read more →CGEN▼ -5.4%on this news
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
Compugen Ltd. (Nasdaq: CGEN) announced its selection for two oral presentations at the Keystone Symposium on Cancer Immunotherapy, scheduled for March 17-21, 2024, in Whistler, Canada. The presentations will cover novel insights into T cell biology and the TIGIT and VISTA pathways. This selection reflects the company's advancements in cancer immunotherapy research and its commitment to developing innovative therapeutics. Details of the presentations will be made available on Compugen's website on the presentation day.
Read more →CGENCompugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
Compugen Ltd. announced its participation in the upcoming AACR annual meeting, where it will present data on its immuno-oncology pipeline. The company intends to highlight its advancements, particularly on the PVRIG and IL-18 binding protein cancer targets, with two poster presentations scheduled for April 2024. These presentations will cover the unique biology of PVRIG and the therapeutic potential of its first-in-class anti-IL-18 binding protein antibody, COM503. The event aims to underscore Compugen's progress in addressing immunotherapy resistance and expanding treatment options.
Read more →CGEN▼ -13.6%on this newsshared move
Compugen Reports Fourth Quarter and Full Year 2023 Results
Compugen Ltd. reported its financial results for the fourth quarter and full year 2023, marking a significant achievement with a net profit of $9.7 million for Q4. The company has entered a partnership with Gilead for its COM503 program, receiving an upfront payment of $60 million. Compugen is optimistic about a catalyst-rich 2024, with several data readouts set from their diverse portfolio, although it faces challenges in treating difficult indications. The firm maintains a solid balance sheet that will support operations until 2027.
Read more →CGEN▲ +9.4%on this news
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
Compugen Ltd. has announced that its management will participate in a fireside chat at the upcoming Leerink Partners Global Biopharma Conference in Miami Beach on March 11, 2024. The event will include a live webcast available on Compugen's Investor Relations website. The company, focused on cancer immunotherapy, is known for its innovative drug discovery capabilities, with a pipeline that includes potential first-in-class therapies. Compugen's engagement in this major conference highlights its role in advancing cancer treatments.
Read more →CGENCompugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
Compugen Ltd. announced it will release its fourth quarter and full year 2023 financial results on March 5, 2024, prior to the opening of U.S. financial markets. The management will hold a conference call and webcast at 8:30 AM ET to review the results and provide a corporate update. Compugen is noted for its work in cancer immunotherapy and has several proprietary candidates in its pipeline.
Read more →CGENCompugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
Compugen Ltd. has announced the appointment of Dr. Michelle Mahler as its new Chief Medical Officer, effective March 1, 2024. She succeeds Dr. Henry Adewoye, who is departing after six years. Dr. Mahler, who previously served as Vice President of Clinical Development at Compugen since October 2023, will oversee the development of key programs like COM701, COM902, and COM503. Her experience includes significant roles in other biotech firms, and she emphasizes the importance of addressing unmet needs in cancer immunotherapy.
Read more →CGEN▲ +6.9%on this news
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
Compugen Ltd. has announced that it has regained compliance with Nasdaq's minimum bid price requirement as of January 4, 2024. This follows a prior notification on November 3, 2023, indicating that the company had failed to maintain the required minimum bid price of $1.00. The compliance was restored after the company's shares closed at or above the $1.00 threshold for ten consecutive business days. Compugen continues to develop innovative cancer immunotherapy candidates, including COM701 and COM902.
Read more →CGEN▲ +6.9%on this news
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Compugen Ltd. has announced that it will receive a $10 million milestone payment following the dosing of the first patient in AstraZeneca's Phase 3 ARTEMIDE-Bil01 trial of the bispecific antibody rilvegostomig for biliary tract cancer. This collaboration allows AstraZeneca to develop bispecific and multispecific antibody products using Compugen's technology. The trial is expected to recruit approximately 750 participants and represents a significant step for both firms in the oncology sector.
Read more →CGEN▲ +174%on this news
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
Compugen Ltd. has announced a conference call to discuss its exclusive license agreement with Gilead for the development of COM503, a novel anti-IL-18 binding protein program. This potential first-in-class antibody aims to target IL-18 to treat various tumor types. The agreement signifies a strategic partnership that could enhance Compugen's position within the immunotherapy landscape, with COM503 currently in IND enabling studies.
Read more →CGEN▲ +174%on this news
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Compugen Ltd. announced it will be eligible for a $10 million milestone payment from AstraZeneca upon the dosing of the first patient in the Phase 3 ARTEMIDE-Bil01 trial for rilvegostomig, a PD-1/TIGIT bispecific antibody. The trial aims to enroll approximately 750 patients with biliary tract cancer, and the results may have significant implications for treatment options. This advancement further solidifies the partnership between Compugen and AstraZeneca, highlighting the potential of rilvegostomig and Compugen's capabilities in cancer immunotherapy development.
Read more →CGEN▼ -5.9%on this news· ran to -20% by day 3
Compugen Reports Third Quarter 2023 Results
Compugen Ltd. reported its financial and operational results for Q3 2023, highlighting progress in various clinical studies. Notable advancements include the Phase 3 trial of rilvegostomig for biliary tract cancer and completed enrollment for a proof-of-concept study involving COM701 in colorectal cancer. Clinical data presented indicates COM701's efficacy in immunotherapy-resistant tumors and suggests PVRL2 as a potential biomarker. However, the company reported a net loss, though an improvement compared to the same period last year, and a decrease in cash reserves.
Read more →CGENCompugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy COM701 + nivolumab + BMS-986207 (anti-TIGIT) resulted in clinically meaningful durable partial responses 16 months in platinum resistant ovarian...
Compugen Ltd. presented promising results at the SITC conference regarding its COM701 combination therapy in treating platinum-resistant ovarian cancer and metastatic breast cancer. Notable findings indicate that COM701, in combination with nivolumab and BMS-986207, achieved durable partial responses exceeding 16 months in ovarian cancer patients. Importantly, the preliminary data on PVRL2 levels suggests a potential predictive biomarker for clinical benefit. The findings highlight a favorable safety profile while acknowledging challenges in a competitive treatment landscape.
Read more →CGENCompugen Announces Receipt of Nasdaq Minimum Bid Price Notification
Compugen Ltd. received a notification from Nasdaq regarding its ordinary shares failing to meet the minimum bid price requirement. The company has 180 days to regain compliance and can appeal a potential delisting. Despite this setback, Compugen continues its therapeutic developments in cancer immunotherapy. The notification does not currently impact the trading of its shares.
Read more →CGEN▲ +10.9%on this newsshared move
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer
Compugen Ltd. announced that it will present new data on its pre-clinical asset COM503, an anti-IL18BP antibody, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 3-5, 2023. The data demonstrate that COM503 can inhibit tumor growth while avoiding systemic side effects associated with traditional cytokine treatments. The company emphasizes its unique approach to leveraging endogenous IL-18 to enhance anti-tumor immune responses. The upcoming presentations will include both oral and poster sessions showcasing these findings.
Read more →CGEN▲ +6.4%on this news
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023
Compugen Ltd. announced that it will release its third quarter 2023 financial results on November 7, 2023, before U.S. markets open. A conference call will follow at 8:30 AM ET to review the results and provide a corporate update. This update will include discussion of data presented at the Society for Immunotherapy of Cancer Annual Meeting happening from November 1-5, 2023. Compugen is focused on developing cancer immunotherapies and has produced several innovative therapeutic candidates.
Read more →CGENCompugen to Present at Single Cell Genomics 2023 Meeting
Compugen Ltd. announced its participation at the Single Cell Genomics 2023 meeting from October 9-11, 2023, in Engelberg, Switzerland. The company will present data on single-cell spatial transcriptomics, focusing on the expression of the immune checkpoint PVRIG and its relevance in cancer treatment. The poster titled 'Elucidating the Mechanism of Action of the Novel Immune Checkpoint PVRIG' will be presented by Roy Granit, Ph.D. This event signifies Compugen's commitment to advancing cancer immunotherapy research and showcases its innovative approaches in the field.
Read more →CGENCompugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
Compugen Ltd. announced the granting of a new Japanese patent for a triple combination therapy using anti-PVRIG, anti-TIGIT, and anti-PD-1 antibodies to treat cancer. This patent, No. JP7348072B2, enhances Compugen's existing intellectual property and supports their position in the competitive landscape of cancer immunotherapy. The patent is crucial for establishing a competitive edge in addressing cancer treatment challenges, particularly in overcoming resistance to current immunotherapy methods. Compugen's innovative approach aims to benefit patients without chemotherapy.
Read more →CGENCompugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023
Compugen Ltd. announced its plans to present new clinical and pre-clinical data at the upcoming SITC 2023 conference. The presentations will include an oral presentation on IL-18BP blockade and multiple poster presentations focusing on combination therapies for cancer treatment. This highlights Compugen's potential to expand the reach of its cancer immunotherapies to new patient populations. The event will take place from November 3-5, 2023, in San Diego, California.
Read more →CGENCompugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Compugen Ltd. announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference, where it will present its innovative cancer immunotherapy approaches. The conference presentation will be available on their website from September 11, 2023, for 30 days. Compugen is recognized for its predictive computational capabilities, and it has several promising product candidates, including COM701 and COM902, which target distinct pathways for cancer treatment. The company is headquartered in Israel, with additional offices in San Francisco, CA.
Read more →CGEN▼ -8%on this news
Compugen Reports Second Quarter 2023 Results
Compugen Ltd. (CGEN) reported its financial results for the second quarter of 2023 and outlined progress in its clinical trials. The company is advancing enrollment in two proof-of-concept studies targeting colorectal and ovarian cancers, with initial findings expected by year-end. While net losses remain a concern, the firm has enough financial resources to support its operations through 2024, and it plans to present new data from various studies in the second half of the year. Additionally, the validation of its patent strategy may strengthen its market position.
Read more →CGEN▼ -5.9%on this news
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023
Compugen Ltd. announced it will release its second quarter 2023 financial results on August 7, 2023, prior to U.S. market opening. The company will also hold a conference call at 8:30 AM ET on the same day to discuss the results and provide a corporate update. Compugen focuses on cancer immunotherapy through computational target discovery, and its pipeline includes promising candidates like COM701 and COM902. The call will be accessible via telephone and live webcast, with a replay available afterward.
Read more →CGENCompugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party
Compugen Ltd. announced that the European Patent Office upheld their patent EP3258951B1, covering Anti-PVRIG Antibodies for cancer treatment. The decision came after opposition from GSK and an anonymous third party, but the ruling affirms the patent's broad claims. The CEO expressed satisfaction with this outcome, as it aligns with the company's strategy to discover novel targets in immunotherapy. Compugen is currently exploring combinations of PVRIG, TIGIT, and PD-1 in clinical studies aimed at specific cancer types.
Read more →CGEN▼ -7.9%on this news
Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study
Compugen Ltd. has initiated a proof-of-concept study by dosing the first patient with a triple immunotherapy combination that includes COM701, COM902, and pembrolizumab for treating platinum-resistant ovarian cancer. This study builds upon previous clinical data that suggest potential benefits of combined treatment strategies. The study aims to enhance understanding of these therapies and identify which patients may best respond. Initial findings from the study are anticipated by the end of 2023.
Read more →CGEN▲ +6.7%on this news· ran to +21% by day 1
Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer COM701 in combination with nivolumab and BMS-986207 (anti-TIGIT) resulted in encouraging confirmed durable partial responses (overall response rate...
Compugen Ltd. announced promising preliminary data on its investigational drug COM701 in combination with nivolumab and BMS-986207, showing durable anti-tumor activity in patients with recurrent, metastatic MSS endometrial cancer. The therapy achieved a 22% overall response rate and a 44% disease control rate. Notably, one patient demonstrated a partial response lasting nearly 7 months after previously failing standard treatments. These findings were presented at the ASCO Annual Meeting, underscoring Comugen's commitment to addressing significant unmet medical needs in challenging cancer cases.
Read more →CGEN▲ +10%on this news
Compugen Reports First Quarter 2023 Results
Compugen Ltd. announced its financial results for the first quarter of 2023, providing updates on its clinical developments and cash position. The company reported a cash balance of $74.3 million, expected to support operations until at least the end of 2024. Compugen is set to deliver findings from studies utilizing a triple blockade of PVRIG, TIGIT, and PD-1 in specific cancer types by the year's end. Additionally, promising pre-clinical results for its lead asset, COM503, were shared during the CIMT meeting.
Read more →CGENCompugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023
Compugen Ltd. will host a virtual DNAM-1 Axis Investor Event on May 23, 2023, featuring Dr. Drew Pardoll from Johns Hopkins University. The event will discuss the company's DNAM-1 axis hypothesis, which proposes a novel approach by blocking PVRIG, TIGIT, and PD-1 simultaneously to improve immune responses in certain cancer patients. A short presentation will be followed by an interactive Q&A session, emphasizing Compugen's commitment to advancing cancer immunotherapy.
Read more →CGENCompugen to Present at the JMP Securities Life Sciences Conference
Compugen Ltd. (CGEN) announced its management will present at the JMP Securities Life Sciences Conference on May 16, 2023. The virtual presentation highlights the company's ongoing efforts in cancer immunotherapy and its proprietary product candidates. Compugen has developed notable therapies such as COM701 and COM902, along with a partnered program, rilvegostomig, currently in Phase 2. The webcast of the presentation will be available on their Investor Relations website, underscoring their commitment to investor engagement.
Read more →CGENCompugen to Release First Quarter 2023 Results on Monday, May 15, 2023
Compugen Ltd. announced that it will release its financial results for the first quarter of 2023 on May 15, 2023. The announcement highlights the company's ongoing commitment to transparency, as they will host a conference call and webcast to discuss the results and provide a corporate update. Compugen is focused on developing cancer immunotherapies through its proprietary product candidates and partnerships, continuing to advance its therapeutic pipeline.
Read more →CGENCompugen to Present New Clinical Data Showing Preliminary Anti-Tumor Activity of COM701 Triple Combination in Recurrent MSS-Metastatic Endometrial Cancer at ASCO 2023
Compugen Ltd. announced that it will present new clinical data on COM701 in combination with BMS-986207 and nivolumab at the upcoming ASCO annual meeting. This presentation will focus on the preliminary anti-tumor activity of this combination treatment for patients with recurrent, metastatic MSS endometrial cancer. The session is scheduled for June 5, 2023, and may reveal significant insights into the efficacy of this innovative therapeutic approach.
Read more →CGENCompugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting
Compugen Ltd. has announced its intention to present pre-clinical data on its lead asset, COM503, at the upcoming 20th CIMT annual meeting. COM503 is designed as a high-affinity anti-IL18 binding protein antibody that aims to unleash the immune response against tumors by freeing endogenous IL-18. The company plans to file for an IND in 2024, showcasing a potentially innovative approach to cancer treatment. The event will take place in Mainz, Germany, on May 3-5, 2023.
Read more →CGENCompugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023
Compugen Ltd. announces new research aimed at enhancing the detection and study of the novel target PVRIG, facilitated by corrections to the GENCODE gene model. This research will be presented at the upcoming AACR annual meeting in April 2023. Compugen's efforts are focused on advancing cancer immunotherapies, including proof-of-concept studies for its products targeting PVRIG and TIGIT pathways. However, the company acknowledges the inherent risks associated with clinical development and the uncertain outcomes of their therapeutics.
Read more →CGENCompugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
Compugen Ltd. announced its participation in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023. The event aims to discuss its advancements in cancer immunotherapy, particularly focusing on its proprietary product candidates. The company has developed innovative therapies to address various mechanisms of immune resistance in cancer. A live webcast will be available for investors and the general public, with a replay accessible for 90 days post-event.
Read more →CGENCompugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study
Compugen Ltd. has announced the dosing of the first patient in a proof-of-concept study for a triple combination therapy involving COM701, COM902, and pembrolizumab for metastatic microsatellite stable colorectal cancer (MSS CRC). The study aims to build on previously reported clinical benefits from dual combination therapies. Initial findings are anticipated by the end of 2023, and the company hopes to identify optimal patient responses to this novel treatment strategy. The trial is particularly significant for patients with limited existing treatment options.
Read more →CGENCompugen Reports Fourth Quarter and Full Year 2022 Results
Compugen Ltd. reported its fourth quarter and full year 2022 financial results, highlighting significant progress in its clinical programs, particularly in treating difficult cancer types with novel immunotherapies. The company is poised to begin dosing patients in two proof of concept studies in microsatellite stable colorectal cancer and platinum resistant ovarian cancer in the first half of 2023. With a solid cash position of approximately $83.7 million, Compugen anticipates sufficient funding through at least the end of 2024. The report also included details of recent revenue generation and projected financial figures for 2023.
Read more →CGEN▲ +6.3%on this news
Rilvegostomig, AstraZeneca
Compugen Ltd. announced that AstraZeneca's PD-1/TIGIT bi-specific antibody, rilvegostomig, is set to enter Phase 3 clinical trials in 2023. The partnership continues to expand with AstraZeneca's ongoing Phase 2 development of rilvegostomig across various indications, including non-small cell lung cancer and gastric cancer. The agreement allows AstraZeneca to use Compugen’s COM902 for developing bi-specific antibodies, presenting significant milestone payments to Compugen as the program progresses.
Read more →CGENCompugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023
Compugen Ltd. announced that it will release its fourth quarter and full year 2022 financial results on February 27, 2023. The announcement includes a scheduled conference call and webcast at 8:30 AM ET for stakeholders to review the results and receive a corporate update. Compugen, a clinical-stage cancer immunotherapy company, is recognized for its computational target discovery capabilities and has multiple product candidates in its pipeline.
Read more →CGEN▼ -6.3%on this newsshared move
Compugen to Present at the SVB Securities Global Biopharma Conference
Compugen Ltd. announced it will present at the SVB Securities Global Biopharma Conference on February 16, 2023. The company specializes in cancer immunotherapy and has developed several proprietary product candidates, including COM701 and COM902. Compugen's therapeutic pipeline also includes various early-stage immuno-oncology programs addressing immune resistance mechanisms. This presentation serves to highlight the company's advancements and innovations in the field of cancer treatment.
Read more →CGENCompugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview
Compugen Ltd. (NASDAQ: CGEN) will participate in the JMP Securities C-Suite Series with a virtual fireside chat scheduled for January 30, 2023. CEO Dr. Anat Cohen-Dayag and the management team will discuss the company's advancements in cancer immunotherapy, especially regarding the DNAM-1 axis. Compugen, known for its predictive computational discovery, has multiple product candidates aimed at treating solid tumors and is advancing its latest candidate, COM503, towards pre-IND studies.
Read more →CGENCompugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer COM701 in combination with nivolumab ± BMS-986207 (anti-TIGIT) in heavily pretreated patient population, resulted in encouraging durable confirmed...
COM701 in combination with nivolumab ± BMS-986207 (anti-TIGIT) in heavily pretreated patient population, resulted in encouraging durable confirmed partial responses (overall response rate 20% (n=20) triple study, 10% (n=20) dual study and disease control rate (45%) for both), sup
Read more →CGEN▼ -5.8%on this newsshared move
Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 (anti-TIGIT) demonstrated encouraging 20% overall response rate and 40% disease...
At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 (anti-TIGIT) demonstrated encouraging 20% overall response rate and 40% disease control rate in heavily pretreated patients with platinum resistant ovarian cancer and was well tolerated, with all responders remai
Read more →CGENCompugen to Participate in the JMP Securities Hematology and Oncology Summit
HOLON, Israel, Nov. 29, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Anat Cohen-Dayag, Ph.D., President and CEO, and additional members of its management team
Read more →CGENCompugen to Receive Milestone Payment Triggered by AstraZeneca
Advancement of AZD2936, a PD-1/TIGIT bispecific antibody derived from COM902, into Phase 2, triggers $7.5 million milestone payment from AstraZeneca HOLON, Israel, Nov. 16, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pio
Read more →CGEN▼ -9.3%on this newsshared move
Compugen Reports Third Quarter 2022 Results
New encouraging preliminary clinical data, presented at SITC 2022, showing anti-tumor activity supported by potent immune activation in the tumor microenvironment following combination of COM701 and nivolumab in metastatic MSS-CRC patients. Further clinical evaluation of COM701 a
Read more →CGENCompugen to Participate in the Stifel Healthcare Conference
HOLON, ISRAEL, Nov. 8, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Anat Cohen-Dayag, Ph.D., President and CEO, and additional members of its management team w
Read more →CGENCompugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients COM701 in combination with nivolumab demonstrated encouraging 12% ORR in 3L+ MSS-CRC patients with liver metastases, compared to 0% ORR historically...
COM701 in combination with nivolumab demonstrated encouraging 12% ORR in 3L+ MSS-CRC patients with liver metastases, compared to 0% ORR historically for other immunotherapies in a U.S. patient population Translational data showed potent immune activation in the tumor microenviro
Read more →CGEN▼ -11.6%on this newsshared move
Compugen Announces Receipt of Nasdaq Delisting Notice
HOLON, Israel, Nov. 2, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on October 31, 2022, it received a notification letter from the Listing Qualifications Dep
Read more →CGEN▲ +8.8%on this news· ran to +19% by day 1shared move
Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022
HOLON, Israel, Oct. 31, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its third quarter 2022 financial results on Monday, November 14,
Read more →CGEN▲ +6.8%on this news· ran to +20% by day 3shared move
Compugen to Present New Clinical Data at ESMO-IO
Clinical data from COM701/nivolumab ± BMS-986207 combination studies in patients with platinum resistant ovarian cancer Clinical data from COM701±nivolumab study in patients with metastatic NSCLC who received prior immune checkpoints HOLON, Israel, Oct. 26, 2022 /PRNewswire/ --
Read more →CGENCompugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022
Clinical data from dual combination COM701/nivolumab MSS-CRC cohort expansion study Research data on differentiation of PVRIG from other immune checkpoints HOLON, Israel, Oct. 6, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company an
Read more →CGEN▼ -10.6%on this news
Compugen Letter to Shareholders
HOLON, Israel, Sept. 22, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, is pleased to issue the following letter to shareholders: As we approach the Jewish New Year, I am taking th
Read more →CGENCompugen Announces Appointment of Alberto Sessa as Chief Financial Officer
HOLON, Israel, Sept. 12, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Alberto Sessa has been appointed Chief Financial Officer (CFO) and member of the managem
Read more →CGENCompugen to Participate in Upcoming Fierce Biotech Summit
YaronTurpaz, Ph.D., SVP and Senior Advisor, Computational Discovery, Compugen to participate in a panel discussion on leveraging artificial intelligence and machine learning to advance discovery and accelerate drug development. HOLON, Israel, Sept. 7, 2022 /PRNewswire/ -- Compug
Read more →CGENCompugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japan
HOLON, Israel, Aug. 24, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Japan Patent Office has granted Compugen a new composition of matter and use patent c
Read more →CGENCompugen Expands anti-PVRIG COM701 Intellectual Property Portfolio
HOLON, Israel, Aug. 8, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the European Patent Office has granted Compugen a new patent covering anti-PVRIG antibodie
Read more →CGENCompugen Reports Second Quarter 2022 Results
Prioritized two indications, MSS-CRC and NSCLC, utilizing fully owned assets, COM701 and COM902 Focus on MSS-CRC and NSCLC expected to provide highest probability of success and support future path to registration Focused development plan results in strategic decision to wind d
Read more →CGEN▲ +10.9%on this news
Compugen to Release Second Quarter Results on Thursday, August 4, 2022
HOLON, Israel, July 21, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its second quarter financial results on Thursday, August 4, 2022
Read more →CGEN▼ -7.2%on this news
Compugen to Present at Upcoming Industry Conferences
HOLON, ISRAEL, June 27, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that members of its management team will present at the following industry conferences in Euro
Read more →CGENCompugen to Present at Upcoming Investor Conferences
HOLON, Israel, June 1, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the following investor conferences: Event: Jefferies Healthcar
Read more →CGENCompugen Reports First Quarter 2022 Results
Triple blockade of PVRIG/TIGIT/PD-1 may be required to optimize clinical responses COM701, a unique check point inhibitor, with potential to recruit additional T cells to the TME COM902 has the potential to be a best-in-class anti-TIGIT antibody On track to deliver clinical da
Read more →CGENCompugen Announces CFO Departure
HOLON, Israel, May 10, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Mr. Ari Krashin, Chief Financial Officer and Chief Operating Officer of Compugen Ltd. (the
Read more →CGENCompugen to Release First Quarter 2022 on Monday, May 16, 2022
HOLON, Israel, May 2, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its first quarter 2022 financial results on Monday, May 16, 2022,
Read more →CGENCompugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment Compugen Ltd. (Nasdaq: CGEN), ( Compugen, the Company ), a clinical-stage cancer immunotherapy company and a pioneer in computational target...
HOLON, Israel, March 21, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ("Compugen," the "Company"), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will give a presentation today on exploring the immune-t
Read more →CGEN▼ -7.5%on this news
Compugen To Present New Insights into the Tumor Microenvironment Using Single Cell Spatial Transcriptomics at Keystone Symposium
HOLON, Israel, March 14, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it has been selected to give an oral presentation on exploring the immune-tumor microenv
Read more →CGEN▲ +10.6%on this newsshared move
Compugen to Present at the Oppenheimer 32nd Annual Global Healthcare Conference
HOLON, Israel, March 9, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the Oppenheimer 32nd Annual Global Healthcare Conference (virt
Read more →CGEN▲ +10.6%on this newsshared move
Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise for Treatment of Multiple Myeloma
HOLON, Israel, March 9, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN),("Compugen," the "Company"), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the presentation of new research suggesting that targeting PVRIG a
Read more →CGEN▲ +6.2%on this news
Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
HOLON, Israel, Feb. 24, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice P
Read more →CGEN▲ +6.2%on this news
Compugen Reports Fourth Quarter and Full Year 2021 Results
HOLON, Israel, Feb. 24, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today reported financial results for the fourth quarter ended December 31, 2021, and fu
Read more →CGENCompugen to Release Fourth Quarter and Full Year 2021 Results on Thursday, February 24, 2022
HOLON, Israel, Feb. 10, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its fourth quarter and full year 2021 financial results on Thursday,
Read more →CGENCompugen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
HOLON, Israel, Feb. 9, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that management will present at the 11th Annual SVB Leerink Global Healthcare Conference (virtual),
Read more →CGENCompugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies
HOLON, Israel, Jan. 18, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ-GM: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the United States Patent and Trademark Office (USPTO) has granted Compugen a new patent co
Read more →CGENCompugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit
HOLON, Israel, Dec. 9, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of preliminary translational data from patient biopsies demonstrating immune activ
Read more →CGEN▼ -18%on this news· ran to -31% by day 3
Compugen Reports Third Quarter 2021 Results
- COM701, Opdivo® and BMS-986207, triple combination dose escalation Phase 1/2 data being presented at 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) clears the path to studies in select biomarker informed tumor types - COM902 monotherapy dose escalation P
Read more →CGEN▼ -18%on this news· ran to -31% by day 3
Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of COM902 a High Affinity Anti-TIGIT Antibody at SITC 2021
HOLON, Israel, Nov. 12, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of preliminary results from its ongoing Phase 1 dose escalation study evaluating
Read more →CGEN▼ -18%on this news· ran to -31% by day 3
Compugen Presents Initial Translational Data Supporting the Differentiation of PVRIG Compared to TIGIT and PD-1 as a Novel Checkpoint on the DNAM Axis at SITC 2021
HOLON, Israel, Nov. 12, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of new translational preliminary data detailing the differentiated profile of PVR
Read more →CGEN▲ +14%on this newsshared move
Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment
HOLON, Israel, Nov. 11, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that Bristol Myers Squibb (NYSE: BMY) completed its $20 million investment in Compugen in consider
Read more →CGENCompugen to Release Third Quarter 2021 Results on Friday, November 12, 2021
HOLON, Israel, Oct. 26, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its third quarter 2021 financial results on Friday, November 12, 202
Read more →CGENCompugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902
HOLON, Israel, Oct. 4, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that Compugen is entitled to receive a $6 million milestone payment from AstraZeneca (LSE: AZN) (ST
Read more →CGENCompugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021
HOLON, Israel, Oct. 1, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that new clinical and preclinical data will be presented at the 36th Annual Meeting of the Society
Read more →CGENCompugen to Present at the Cantor Global Healthcare Conference
HOLON, Israel, Sept. 14, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Cantor Global Healthcare Conference on Thursda
Read more →CGENCompugen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
HOLON, Israel, Aug. 26, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Morgan Stanley 19th Annual Global Healthcare Co
Read more →CGENCompugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development
HOLON, Israel, Aug. 19, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that a bispecific antibody of AstraZeneca derived from COM902, Compugen's high affi
Read more →CGEN▲ +7.8%on this news
Compugen Reports Second Quarter 2021 Results
HOLON, Israel, July 28, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the second quarter ended June 30, 2021. "Our continued execution in the clin
Read more →CGENCompugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb
HOLON, Israel, July 19, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the cohort expansion arm of the Phase 1/2 study evaluatin
Read more →CGENCompugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies
HOLON, Israel, July 15, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery today announced that the first patient has been dosed in its Phase 1 clinical study evaluating the dual combination
Read more →CGENCompugen to Release Second Quarter 2021 Results on Wednesday, July 28, 2021
HOLON, Israel, July 14, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its second quarter 2021 financial results on Wednesday, July 28, 202
Read more →CGENCompugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study
HOLON, Israel, June 30, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the combination expansion cohort of its ongoing Phase 1 c
Read more →CGENCompugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis
HOLON, Israel, June 29, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of additional research supporting the differentiation of PVRIG from other immune
Read more →CGENCompugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting
HOLON, Israel, June 8, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, presented updated data from its Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dos
Read more →CGENCompugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities
HOLON, Israel, June 1, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that members of its senior management team will participate in a virtual event to discuss data from
Read more →CGENCompugen Reports First Quarter 2021 Results
HOLON, Israel, May 13, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the first quarter ended March 31, 2021. "2021 will be an important year of mi
Read more →CGENCompugen to Participate at SITC
HOLON, Israel, May 11, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that Eran Ophir, Ph.D., Vice President Research and Drug Discovery at Compugen, will participate at
Read more →CGENCompugen Announces Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Discovered by Compugen
HOLON, Israel, May 10, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has expanded its research collaboration with Johns Hopkins University to include studies in
Read more →CGENCompugen to Release First Quarter 2021 Results on Thursday, May 13, 2021
HOLON, Israel, May 3, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its first quarter 2021 financial results on Thursday, May 13, 2021 bef
Read more →CGENCompugen to Present Data Update on COM701 Phase 1 Clinical Trial at the American Society of Clinical Oncology 2021 Annual Meeting
HOLON, Israel, April 29, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701, a first-in-
Read more →CGENCompugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy
HOLON, Israel, April 27, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of a peer-reviewed article titled "COM902, a Novel Therapeutic Antibody Targeting
Read more →CGENCompugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy
HOLON, Israel, March 9, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of a review article titled "Therapeutic Targeting of Checkpoint Receptors within t
Read more →CGENCompugen to Present at the Oppenheimer 31st Annual Healthcare Conference
HOLON, Israel, March 8, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Oppenheimer 31st Annual Healthcare Conference (
Read more →CGENCompugen Reports Fourth Quarter and Full Year 2020 Results
HOLON, Israel, Feb. 25, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the fourth quarter and full year ended December 31, 2020. "Our encouraging n
Read more →CGENCompugen Announces Data Update from COM701 Phase 1 Clinical Trial
HOLON, Israel, Feb. 25, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, reported today updated data from its Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and i
Read more →CGENCompugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo®
HOLON, Israel, Feb. 22, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended
Read more →CGENCompugen to Release Fourth Quarter and Full Year 2020 Results on Thursday, February 25, 2021
HOLON, Israel, Feb. 16, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its fourth quarter and full year 2020 financial results on Thursday,
Read more →CGENCompugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products
HOLON, Israel, Dec. 23, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today progress from its ongoing license agreement with AstraZeneca (LSE: AZN) (STO: AZN) (NASDAQ: AZN) u
Read more →CGENCompugen Reports Third Quarter 2020 Results
HOLON, Israel, Nov. 5, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the third quarter ended September 30, 2020. "We have reached an exciting mile
Read more →CGENCompugen Further Expands Patent Portfolio for TIGIT Inhibitor COM902 with Composition of Matter Patent in China
HOLON, Israel, Nov. 2, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the China National Intellectual Property Administration (CNIPA) has granted the Company a new pa
Read more →CGENCompugen Presents New Research Data Further Supporting PVRIG as a Potentially Promising Target for Cancer Immunotherapy
HOLON, Israel, Oct. 27, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of new research data further supporting PVRIG as a potentially promising target f
Read more →CGENCompugen to Release Third Quarter 2020 Results on Thursday, November 5, 2020
HOLON, Israel, Oct. 22, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its third quarter 2020 financial results on Thursday, November 5, 20
Read more →CGENCompugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientific Advisory Board
HOLON, Israel, Sept. 30, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the addition of Nils Lonberg, Ph.D., to its Scientific Advisory Board (SAB). Dr. Lonberg is a pio
Read more →CGENCompugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb
HOLON, Israel, Sept. 8, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the Phase 1/2 study evaluating the triple combination of
Read more →CGENCompugen to Present at Upcoming September 2020 Investor Conferences
HOLON, Israel, Sept. 3, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the following upcoming virtual investor conferences
Read more →CGENCompugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent
HOLON, Israel, Aug. 28, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted a new patent covering the com
Read more →CGENCompugen Reports Second Quarter 2020 Results
HOLON, Israel, July 30, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the second quarter ended June 30, 2020. "We have reached an exciting phase o
Read more →CGENCompugen to Release Second Quarter 2020 Results on Thursday, July 30, 2020
HOLON, Israel, July 16, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its second quarter 2020 financial results on Thursday, July 30, 2020
Read more →CGENCompugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb
HOLON, Israel, June 1, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration has cleared the investigational new drug (IND) applicati
Read more →CGENCompugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort
HOLON, Israel, May 27, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the monotherapy expansion cohort of its ongoing Phase 1 cl
Read more →CGENCompugen Reports First Quarter 2020 Results
HOLON, Israel, May 6, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the first quarter ended March 31, 2020. "We have entered 2020 well positioned
Read more →CGENCompugen Presents Data Update From Ongoing Phase 1 Trial of COM701 at the 2020 AACR Virtual Annual Meeting
HOLON, Israel, April 27, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, will present updated results from its ongoing Phase 1 dose escalation study of COM701, a first-in-class anti-PVRI
Read more →CGENCompugen to Release First Quarter 2020 Results on Wednesday, May 6, 2020
HOLON, Israel, April 23, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its first quarter 2020 financial results on Wednesday, May 6, 2020
Read more →CGENCompugen Expands Intellectual Property Portfolio for COM701 With New European Composition of Matter Patent
HOLON, Israel, April 22, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has granted the Company a new patent for the composition of C
Read more →CGENCompugen Announces Publication of BAY 1905254 Preclinical Data in Cancer Immunology Research
HOLON, Israel, April 20, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today the publication of a peer reviewed paper titled "Characterization of BAY 1905254, a novel immune ch
Read more →CGENCompugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting
HOLON, Israel, April 14, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701, a first-in-
Read more →CGENCompugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies
HOLON, Israel, April 6, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in its Phase 1 clinical trial of COM902, an immuno-oncology
Read more →CGENCompugen Announces Closing of $75 Million Public Offering of Ordinary Shares
HOLON, Israel, March 17, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the closing of its previously announced underwritten public offering of 8,333,334 ordinary shares
Read more →CGENCompugen Announces Pricing of $75 Million Public Offering of Ordinary Shares
HOLON, Israel, March 12, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the pricing of an underwritten public offering of 8,333,334 ordinary shares at a price to the pub
Read more →CGENCompugen Announces Commencement of Public Offering of Ordinary Shares
HOLON, Israel, March 11, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to
Read more →CGENCompugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study
HOLON, Israel, March 9, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, reported today updated data from its ongoing Phase 1 dose escalation study of COM701 in patients with advanced solid
Read more →CGENCompugen Reports Fourth Quarter and Full Year 2019 Results
HOLON, Israel, Feb. 20, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the fourth quarter and full year ended December 31, 2019. "2019 was a transf
Read more →CGENCompugen Announces Phase 1/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb
HOLON, Israel, Feb. 20, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced its plan to initiate a Phase 1/2 study evaluating a triple combination of Compugen's COM701, an inve
Read more →CGENCompugen to Release Fourth Quarter and Full Year 2019 Results on Thursday, February 20, 2020
HOLON, Israel, Feb. 10, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its fourth quarter and full year 2019 financial results on Thursday,
Read more →CGENCompugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-oncology Symposium
HOLON, Israel, Feb. 7, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targ
Read more →CGENCompugen Announces New U.S. Patent for Methods of Screening for Anti-PVRIG Antibodies
HOLON, Israel, Feb. 4, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent for m
Read more →CGENCompugen Further Expands Intellectual Property Portfolio With New European Patent for Anti-PVRIG Antibodies
HOLON, Israel, Jan. 29, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has granted the Company a new patent for the use of any anti-P
Read more →CGENCompugen Highlights Recent Accomplishments and Previews Upcoming Milestones
HOLON, Israel, Jan. 9, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today provided an update on upcoming milestones for its COM701 and COM902 clinical programs and highlighted 2019 ac
Read more →CGENCompugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development
HOLON, Israel, Jan. 8, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the appointment of Oliver Froescheis, Ph.D., as Senior Vice President, Corporate and Business Devel
Read more →CGENCompugen Added to the NASDAQ Biotechnology Index
HOLON, Israel, Dec. 20, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI). Compugen
Read more →CGENCompugen Reports Third Quarter 2019 Results
HOLON, Israel, Nov. 11, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the third quarter ended September 30, 2019. "Our first presentation of clini
Read more →CGENCompugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe
HOLON, Israel, Nov. 6, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has granted a new patent covering the composition of matter and
Read more →CGENCompugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019
HOLON, ISRAEL, Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preclinical results from its COM902 anti-TIGIT program supporting its potential clinical use in var
Read more →CGENCompugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019
HOLON, Israel, Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preliminary results from its ongoing Phase 1 dose escalation study of COM701, a first-in-class anti
Read more →CGENCompugen Announces FDA Clearance of IND Application for COM902
HOLON, ISRAEL, Nov. 4, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration has cleared its investigational new drug (IND) applicati
Read more →CGENCompugen to Release Third Quarter 2019 Results on Monday, November 11, 2019
HOLON, Isreal, Oct. 28, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its third quarter 2019 financial results on Monday, November 11, 201
Read more →CGENCompugen to Present Data from Ongoing COM701 Phase 1 Clinical Trial at SITC 2019
HOLON, Israel, Oct. 2, 2019 /PRNewswire/ -- October 2, 2019 – Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced it will present three posters at the 34th Annual Meeting of the Society for Immunot
Read more →CGENCompugen Presents Update on COM701 Phase 1 Study at 2019 IGCS
HOLON, Israel, Sept. 19, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced progress in its ongoing Phase 1 clinical study evaluating COM701, a first-in-class therapeutic anti
Read more →CGENCompugen Reports Second Quarter 2019 Results
HOLON, Israel, Aug. 5, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial results for the second quarter ended June 30, 2019. "We continued the stro
Read more →CGENCompugen Second Quarter 2019 Conference Call Scheduled for Monday, August 5, 2019 at 8:30 AM ET
HOLON, ISRAEL, July 22, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Company will release its second quarter 2019 financial results on Monday,
Read more →CGENCompugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody
HOLON, Israel, July 16, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted a new patent covering method
Read more →CGENCompugen Appoints Eran Perry to Its Board of Directors
HOLON, Israel, July 2, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced the appointment of Mr. Eran Perry to its board of directors, effective July 1, 2019. In addition, the
Read more →CGENCompugen Presents Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeting
HOLON, Israel, June 3, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targ
Read more →CGENCompugen to Present at the Jefferies 2019 Healthcare Conference
HOLON, Israel, May 22, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that Anat Cohen-Dayag, PhD, President and CEO, will present a corporate overview and
Read more →CGENCompugen Reports First Quarter 2019 Results
HOLON, Israel, May 20, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial results for the first quarter ended March 31, 2019. "2019 continues to be
Read more →CGENCompugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors
HOLON, Israel, May 20, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that it has dosed the first patient in the combination arm of its Phase 1 study, combining escalating
Read more →CGENCompugen First Quarter 2019 Conference Call Scheduled for Monday, May 20, 2019 at 8:30 AM ET
HOLON, Israel, May 6, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Company will release its first quarter 2019 financial results on Monday, May
Read more →CGENCompugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting
HOLON, Israel, April 3, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody tar
Read more →CGENCompugen Announces Purchase of Company Shares by its Board of Directors and Members of Management
HOLON, Israel, March 26, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its entire board of directors and members of management purchased Company shares on the open m
Read more →CGENCompugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate
HOLON, Israel, March 12, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted two composition of matter pa
Read more →CGENCompugen to Present at the Cowen and Company 39th Annual Health Care Conference
HOLON, Israel, March 5, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that John Hunter, PhD, Chief Scientific Officer, will present a corporate overview
Read more →CGENCompugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-Oncology Symposium
HOLON, Israel, March 1, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting P
Read more →CGENCompugen Reports Fourth Quarter and Full Year 2018 Results and Announces Corporate Restructuring to Streamline Operations
HOLON, Israel, Feb. 26, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial results for the fourth quarter and full year ended December 31, 2018. Com
Read more →CGENCompugen Fourth Quarter and Full Year 2018 Conference Call Scheduled for Tuesday, February 26, 2019 at 8:30 AM ET
HOLON, Israel, Feb. 14, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its fourth quarter and full year 2018 financial results on Tuesday,
Read more →CGENCompugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy
HOLON, Israel, Jan. 22, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced the online publication of preclinical data demonstrating the role of PVRIG as a novel immune checkpo
Read more →CGENCompugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase ...
HOLON, Israel, Jan. 14, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting P
Read more →CGENCompugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy
HOLON, Israel, Nov. 13, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that a patent for COM902, the Company's TIGIT therapeutic antibody candidate, has been issued by t
Read more →CGENCompugen Reports Third Quarter 2018 Results
HOLON, Israel, Nov. 7, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the third quarter ended September 30, 2018. "The last few months have been hi
Read more →CGENCompugen Third Quarter 2018 Conference Call Scheduled for Wednesday, November 7, 2018 at 8:30 AM ET
HOLON, Israel, Oct. 24, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its third quarter 2018 financial results on Wednesday, November 7, 2
Read more →CGENCompugen Announces Clinical Milestone Payment in Cancer Immunotherapy Collaboration With Bayer Following Dosing of First Patient in BAY 1905254 Phase 1 Trial
HOLON, Israel, Sept. 20, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, was informed that Bayer AG dosed the first patient in the Phase 1 clinical trial of BAY 1905254, a first-in-class i
Read more →CGENCompugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial
HOLON, Israel, Sept. 7, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in its Phase 1 clinical trial of COM701, a first-in-class ca
Read more →CGENCompugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
HOLON, Israel, Sept. 5, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the appointment of Jean-Pierre Bizzari, M.D., formerly Executive Vice President and Global Head of
Read more →CGENCompugen Reports Second Quarter 2018 Results
HOLON, ISRAEL, Aug 1, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the second quarter ended June 30, 2018. "The first half of 2018 has been trans
Read more →CGENCompugen Second Quarter 2018 Conference Call Scheduled for Wednesday, August 1, 2018 at 8:30 AM ET
HOLON, Israel, July 18, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its second quarter 2018 financial results on Wednesday, August 1, 20
Read more →CGENCompugen Welcomes FDA Clearance of Bayer
HOLON, Israel, July 2, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN) (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, was informed that the U.S. Food and Drug Administration (FDA) has cleared Bayer AG's investigational new dru
Read more →CGENCompugen Announces FDA Clearance of IND Application for COM701, a First-in-class Immuno-Oncology Therapeutic Antibody
HOLON, Israel, July 2, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on its investigatio
Read more →CGENCompugen Announces $21 Million Registered Direct Offering of Ordinary Shares and Warrants
HOLON, Israel, June 15, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN)(CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has entered into a definitive securities purchase agreement with certain institutio
Read more →CGENCompugen Reports First Quarter 2018 Results
HOLON, Israel, May 9, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the first quarter ended March 31, 2018. "Key developments in the first quarter
Read more →CGENCompugen First Quarter 2018 Conference Call Scheduled for Wednesday, May 9, 2018 at 10:00 AM ET
HOLON, Israel, April 30, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Company will release its first quarter 2018 financial results on Wednesd
Read more →CGENPreclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy
HOLON, Israel, April 17, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that preclinical data presented by Bayer AG at the Annual Meeting of the American
Read more →CGENCompugen Announces Appointment of Henry Adewoye, MD, as Chief Medical Officer
HOLON, Israel, March 26, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the appointment of Dr. Henry Adewoye, to the newly created position of Chief Medic
Read more →CGENCompugen to Present at the Cowen and Company 38th Annual Health Care Conference
HOLON, Israel, March 8, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that Anat Cohen-Dayag, PhD, President and CEO of Compugen, will present a corporat
Read more →CGENCompugen Reports Fourth Quarter and Full Year 2017 Results
HOLON, Israel, Feb. 21, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial results for the fourth quarter and full year ended December 31, 2017. "20
Read more →CGENCompugen Fourth Quarter and Full Year 2017 Conference Call Scheduled for Wednesday, February 21, 2018 at 10:00 AM ET
HOLON, Israel, Feb. 8, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Company will release its fourth quarter and full year 2017 financial result
Read more →CGENCompugen Announces Publication of the Discovery of ILDR2 as a Novel Immune Checkpoint and Its Use for the Treatment of Autoimmune Diseases in Two Back-to-Back Papers in The Journal of Immunology
HOLON, Israel, Feb. 6, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the online publication of the discovery and validation of the ILDR2 protein as a nov
Read more →CGENCompugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the Potential of COM701 for Treating Multiple Solid Tumors
HOLON, Israel, Jan. 18, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced new preclinical data demonstrating distinctive features of the PVRIG pathway and th
Read more →CGENCompugen Announces Presentations at Three Upcoming Cancer Immunotherapy Conferences
HOLON, Israel, January 2, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced upcoming poster and oral presentations on COM701, a first-in-class therapeutic a
Read more →CGENCompugen Reports Third Quarter 2017 Results
HOLON, Israel, Nov. 7, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial results for the third quarter ended September 30, 2017. "We are making imp
Read more →CGENCompugen to Initiate Manufacturing of COM902, its Lead Anti-TIGIT Monoclonal Antibody
HOLON, Israel, Nov. 6, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that it is advancing COM902, its lead anti-TIGIT antibody, into manufacturing in ant
Read more →CGENCompugen to Enter Research Collaboration With Mount Sinai on Novel Myeloid Immuno-Oncology Targets
HOLON, Israel, November 2, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the initiation of a multi-year cancer immunotherapy research collaboration with
Read more →CGENCompugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month
HOLON, Israel, October 26, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced it will present two posters with new data on COM701, the Company's first-in cla
Read more →CGENCompugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET
HOLON, Israel, October 25, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Company will release its third quarter financial results on Tuesday, N
Read more →CGENA New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy
HOLON, Israel, Oct. 9, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, disclosed new data demonstrating the potential of CGEN-15032 as a target for the development of firs
Read more →CGENCompugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month
HOLON, Israel, August 7, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that CGEN-15032, a newly-disclosed novel myeloid and epithelial immuno-oncology t
Read more →CGENCompugen Welcomes Paul Sekhri as its New Chairman of the Board
HOLON, Israel, August 2, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Board of Directors has appointed Paul Sekhri to serve as a Director and
Read more →CGENCompugen Reports Second Quarter 2017 Results
HOLON, Israel, Aug. 2, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial results for the second quarter ended June 30, 2017. Anat Cohen-Dayag, Ph.D
Read more →CGENCompugen Announces Issuance of U.S. Patent for COM701, its Lead Immuno-Oncology Product Candidate
HOLON, Israel, July 25, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery and development company, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for COM701, the Company's lead immuno-oncology therapeutic a
Read more →CGENCompugen Second Quarter 2017 Conference Call Scheduled for Wednesday, August 2, 2017 at 10:00 AM ET
HOLON, Israel, July 24, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, announced today that the Company will release its second quarter financial results on Wednesday, August 2, 2017 before the U.S. financial markets open. Management will hos
Read more →CGENCompugen Presents at ASCO COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical Models
HOLON, Israel, June 5, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, today disclosed new data for its COM701 immuno-oncology therapeutic antibody candidate demonstrating potential for dual- and triple-combination therapy with antibodies targ
Read more →CGENCompugen Provides Update on COM701 and Upcoming Presentations
HOLON, Israel, May 31, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, announced today that it anticipates a delay of several months in the submission of an investigational new drug application (IND) for COM701, Compugen's clinical candidate a
Read more →CGENCompugen Announces Appointment of Dr. Michal Preminger to Board of Directors
HOLON, Israel, May 25, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, today announced that Michal Preminger, PhD, MBA, Executive Director at Harvard University Office of Technology Development's Harvard Medical School site, has been appointed
Read more →CGENCompugen to Present at Two Upcoming Investor Conferences in June
HOLON, Israel, May 23, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, today announced that Dr. Anat Cohen-Dayag, President and Chief Executive Officer, will present at two investor conferences in New York in June: Jefferies Global Healthcare
Read more →CGENCompugen Reports First Quarter 2017 Results
HOLON, Israel, May 9, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, today reported financial results for the first quarter ended March 31, 2017. Anat Cohen-Dayag, Ph.D., CEO and President of Compugen, stated, "During this quarter we saw cont
Read more →CGENCompugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO
HOLON, Israel, May 4, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, announced today that COM701, an antibody product candidate being developed by the Company for immuno-oncology, will be the subject of a poster presentation at the 2017 Ameri
Read more →CGENCompugen First Quarter 2017 Conference Call Scheduled for Tuesday, May 9, 2017 at 10:00 AM ET
HOLON, Israel, April 26, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, announced today that the Company will host a live conference call on Tuesday, May 9, 2017 at 10:00 AM ET to review first quarter 2017 results. Compugen participants on th
Read more →CGENCompugen Announces Lead Therapeutic Candidate COM902 for CGEN-15137/TIGIT Immuno-Oncology Program
HOLON, Israel, March 28, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, announced today the selection of COM902 as the lead clinical antibody candidate for its CGEN-15137/TIGIT T cell checkpoint inhibitor program in immuno-oncology. COM902 fo
Read more →CGENCompugen to Present CGEN-15001 Autoimmune Product Candidate at Upcoming Conferences
HOLON, Israel, March 22, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, announced today that abstracts highlighting CGEN-15001, the Company's autoimmune product candidate, have been accepted for presentation at Keystone Symposia and IMMUNOLOG
Read more →CGENCompugen Announces Addition of Prof. Miriam Merad to Its Scientific Advisory Board
HOLON, Israel, March 8, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading therapeutic discovery company, announced today that Miriam Merad, MD, PhD, Director of the Precision Immunology Institute and Co-Leader of the Cancer Immunology program at the Icahn School of Me
Read more →CGENCompugen Announces Presentations of COM701 Immuno-oncology Pipeline Product and Predictive Discovery Methodology for Novel Immune Checkpoints at AACR
HOLON, Israel, March 2, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading therapeutic discovery company, announced today that two abstracts, the first covering data of its lead pipeline product and another on its predictive discovery methodologies for novel immune che
Read more →CGENCompugen Reports Fourth Quarter and Calendar Year 2016 Results
HOLON, Israel, Feb. 15, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the fourth quarter and year ended December 31, 2016. Anat Cohen-Dayag, Ph.D., CEO and President of Compugen, stated, "Duri
Read more →CGENCompugen Fourth Quarter and Yearend 2016 Conference Call Scheduled for Wednesday, February 15, 2017 at 10:00 AM EST
HOLON, Israel, January 30, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that the Company will host a conference call on Wednesday, February 15, 2017 at 10:00 AM EST to review fourth quarter and yearend 2016 resul
Read more →CGENCompugen's CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, disclosed today new animal model results demonstrating restoration of...
HOLON, Israel, January 4, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, disclosed today new animal model results demonstrating restoration of immune tolerance by CGEN-15001, the Company's lead candidate for treatment of autoimmun
Read more →CGENCompugen Announces Key Highlights from R&D Day
HOLON, Israel, December 7, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, announced today the following key highlights from its R&D Day that took place this morning in NYC: Disclosure of a therapeutic antibody program targeting T
Read more →CGENCompugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint
HOLON, Israel, December 7, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, disclosed today CGEN-15137, its cancer immunotherapy program for TIGIT. TIGIT is an immune checkpoint in the B7/CD28 family which has recently gained broad
Read more →CGENCompugen Appoints Senior Vice President Corporate and Business Development
HOLON, Israel, December 5, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Kirk A. Christoffersen has joined the company in the position of Senior Vice President - Corporate & Business Development. Mr. Christof
Read more →CGENCompugen to Present at 28th Annual Piper Jaffray Healthcare Conference in New York
HOLON, Israel, November 21, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN, a leading predictive drug discovery company, today announced that Dr. Anat Cohen-Dayag, President and Chief Executive Officer of Compugen, will present a corporate introduction and overview at the 28th
Read more →CGENCompugen Immune Checkpoint Program Demonstrates Potential for Development of New Cancer Immunotherapy Treatments
HOLON, Israel, November 11, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today presented new data for its preclinical CGEN-15029 program demonstrating the potential for the development of new cancer immunotherapy treatments for
Read more →CGENCompugen Ltd. Reports 3rd Quarter 2016 Financial Results
HOLON, Israel, Nov. 7, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported its quarterly financial results for the third quarter 2016 and nine months ending September 30, 2016. As previously announced, the Company confir
Read more →CGENCompugen to Host R&D Day on December 7, 2016 in New York
HOLON,Israel, November 3, 2016 /PRNewswire/ -- November 3, 2016 - Compugen Ltd. (NASDAQ: CGEN) will host an R&D Day in New York City on Wednesday, December 7, 2016, from 9:00 am to 11:00 am ET. A live webcast of the event will be available via the Investors section of Compugen's
Read more →CGENCompugen Third Quarter Financial Statements to be Released November 7, 2016
HOLON, Israel, October 10, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that the Company will issue its quarterly financial statements for the third quarter 2016 on Monday, November 7. The Company also announced
Read more →CGENCompugen Discloses Development of Enhanced LINKS Platform Utilized for the Discovery of Myeloid Targets for Cancer Immunotherapy
HOLON, Israel, August 30, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today disclosed that its LINKS computational platform, initially designed for the characterization and differentiation of existing novel drug target candidat
Read more →CGENCompugen Ltd. Reports 2nd Quarter 2016 Financial Results
HOLON, Israel, Aug. 2, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the second quarter ending June 30, 2016. Anat Cohen-Dayag, Ph.D., Compugen's President and Chief Executive Officer, stated,
Read more →CGENCompugen Second Quarter 2016 Conference Call Scheduled for Tuesday, August 2, 2016 at 10:00 AM ET
HOLON, Israel, July 21, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that the Company will host a conference call at 10:00 AM ET on Tuesday, August 2, 2016 to review the second quarter 2016 results. The quarterly
Read more →CGENCompugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program
HOLON, Israel, June 22, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive therapeutic discovery company, today disclosed at the JMP Securities Life Science Conference in NY, COM701 as the lead monoclonal antibody therapeutic candidate for the Company's CGEN
Read more →CGENCompugen to Present at JMP Securities Life Sciences Conference in New York
HOLON, Israel, June 15, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial and Operating Officer, will present a corporate overview and update at the JMP Securities Life Sciences Confer
Read more →CGENCompugen to Present at the Jefferies Global Healthcare Conference in New York
HOLON, Israel, May 23, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial and Operating Officer of Compugen, will present a corporate overview and update at the Jefferies Global Health
Read more →CGENCompugen to Present at the Oppenheimer Annual Israeli Conference in Tel Aviv
HOLON, Israel, May 16, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial and Operating Officer of Compugen, will present a corporate overview and update at the Oppenheimer 17th Annual
Read more →CGENCompugen Ltd. Reports First Quarter 2016 Financial Results
HOLON, Israel, May 10, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the first quarter ended March 31, 2016. Anat Cohen-Dayag, Ph.D., Compugen's President and Chief Executive Officer, stated,
Read more →CGENSteven Holtzman Joins Compugen as Strategic Business Advisor
HOLON, Israel, May 10, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, announced today that Steven Holtzman, former Executive Vice President, Corporate Development of Biogen, has joined Compugen as a strategic business advisor to t
Read more →CGENCompugen First Quarter 2016 Conference Call and Webcast Scheduled for Tuesday, May 10, 2016 at 10:00 AM ET
HOLON, Israel, April 27, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that the Company will host a conference call at 10:00 AM ET on Tuesday, May 10, 2016, to review the first quarter 2016 results. The quarterly r
Read more →CGENCompugen Achieves Preclinical Milestone in Cancer Immunotherapy Collaboration With Bayer
HOLON, Israel, April 18, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN ), a leading predictive drug discovery company, announced today that it has achieved a first preclinical milestone for CGEN-15022 pursuant to its cancer immunotherapy collaboration with Bayer. The collabor
Read more →CGENDr. Elliott Sigal Joins Compugen Ltd. as Strategic Advisor and Prof. Drew Pardoll Appointed Director at Compugen USA, Inc.
HOLON, Israel, April 6, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, announced today that Elliott Sigal, M.D., Ph.D., former Executive Vice President and Director of Bristol-Myers Squibb, has joined Compugen Ltd. as a strategic
Read more →CGENCompugen to Present at the Jefferies Immuno-Oncology Summit in Boston
HOLON, Israel, March 28, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Anat Cohen-Dayag, Ph.D., President and Chief Executive Officer of Compugen, will present an overview of the Company's immuno-oncology pro
Read more →CGENCompugen Presents Results for CGEN-15029 Immuno-Oncology Therapeutic Program
HOLON, Israel, Feb. 29, 2016 /PRNewswire/ -- In an oral presentation today at the New York Academy of Sciences' Emerging Approaches to Cancer Immunotherapy conference, John Hunter, Ph.D., Site Head and Vice President of Antibody R&D at Compugen USA, Inc., a wholly owned subsidiar
Read more →CGENCompugen Ltd. Reports Fourth Quarter and Calendar 2015 Results
HOLON, Israel, Feb. 9, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the fourth quarter and year ended December 31, 2015. Anat Cohen-Dayag, Ph.D., Compugen's President and Chief Executive Offi
Read more →CGENCompugen Fourth Quarter and Yearend 2015 Conference Call Scheduled for Tuesday, February 9, 2016 at 10:00 AM EST
HOLON, Israel, January 26, 2016 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that the Company will host a conference call at 10:00 AM EST on Tuesday, February 9, 2016 to review fourth quarter and yearend 2015 results.
Read more →Competitive Position
How CGEN ranks across every disease it competes inCompetitive Position is a premium feature
See how CGEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial